CTi Biopharma Corp

CTi Biopharma — Cell Therapeutics — Investor Presentation (September 2012)

37 slides from CTi Biopharma's investor presentation, Sep 10, 2012

  1. Slide 1: Cell Therapeutics, Inc. Company Overview

    MPN Pacritinib Phase 3* MDS/AML Tosedostat Phase 3* NHL Pixuvri™ Marketed (EU) Cell Therapeutics, Inc. Company Overview * Phase 3 ready. Covering a Spectrum of Blood Related Cancers Exhibit 99.1

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties th

  3. Slide 3: Company Overview

    Company Overview Hematology/Oncology-focused biotechnology company 1 commercial product • Pixuvri ™ : for the treatment of non-Hodgkin's lymphoma (“NHL”) - Conditional Marketing Authorization May 2012- E.U. launch September - Attractive “niche” market ~16,000 patients (1) ; 10 yrs market exclusivity

  4. Slide 4: Current Pipeline

    Current Pipeline Third-line r/r aggressive NHL (PIX301) Second-line r/r aggressive NHL (PIX306) First-line aggressive NHL (PIX203) Myelofibrosis (<100,000plts) (1) Primary Myelofibrosis Relapsed Lymphoma First-line or r/r Myelodysplastic Syndrome Elderly high-risk r/r AML (OPAL) Maintenance therapy

  5. Slide 5: Investment Highlights

    Investment Highlights Pixuvri Approved in E.U. Pacritinib is a Differentiated JAK2 Inhibitor Leading, Late-Stage Oncology Franchise Tosedostat has Shown Encouraging Data in AML/MDS Significant Upcoming Milestones • Late-stage portfolio focused on blood-related cancers • Deep pipeline with 1 product

  6. Slide 6: Recent Strategic Initiatives

    Recent Strategic Initiatives Reduced Projected Monthly Cash Burn from an average of ~$5.5mm to ~$4.5mm Initiation of Pacritinib Phase 3 Trial to Q4 2012 Pixuvri Pre-launch Activities in Support of a September 2012 Launch New Hires with Significant Industry and Operational Expertise Implemented Rever

  7. Slide 7: Executive Management Team

    Executive Management Team Officers Position Experience James Bianco, MD Principal Founder, President & Chief Executive Officer, and Director • Chief architect of CTI’s portfolio strategy and has secured more than $1.6bn in operating capital • Previously was an Assistant Member in the clinical resear

  8. Slide 8: Pixuvri

    8 Pixuvri

  9. Slide 9: Pixuvri: Addresses an Unmet Need

    Pixuvri™: Addresses an Unmet Need Anthracyclines: most active class of chemotherapy • Cornerstone agents for NHL, AML, sarcoma, breast • Cumulative cardiac damage is dose limiting Pixuvri™ • Lacks structural motifs that lead to cardiotoxicity - Significant reduction in biochemical, echo-cardiographi

  10. Slide 10: Pixuvri: Conditional Marketing Authorisation

    Pixuvri™: Conditional Marketing Authorisation 3 rd /4 th line aggressive B-cell NHL

  11. Slide 11: Comment

    Comment Pocantrone dimaleate versus other chemotherapeutic agents asa single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: Pixantrone: a new agent for relapsed aggressive lymphomas ‘aphase 3, multicentre, open-label, randomised tral

  12. Slide 12: Pixuvri: First to Market for r/r aggressive B-cell NHL

    Pixuvri™: First to Market for r/r aggressive B-cell NHL Pixuvri (n=70) Comparator (n=70) P Value Pixuvri (n=50) Comparator (n=49) P value CR/CRu 20% 5.7% 0.021 ORR 40% 14.3% 0.001 PFS 5.3mos 2.6mos HR=0.60 0.005 OS 10.2mos 7.6mos HR=0.79 0.25 CR/CRu 28% 4.1% 0.002 ORR 48% 12.2% <0.001 PFS 5.7mos 2.8

  13. Slide 13: Pixuvri: EU Commercial Opportunity

    Pixuvri™: EU Commercial Opportunity Market research supports potential peak penetration ~8,125 patients/year* Market access (pricing) strategy* • Quantitative benefit over physician choice • CR statistically correlative with OS • EU List Price corridor $29,500 - $35,000 - Allows for potential net ex

  14. Slide 14: Pixuvri: U.S. Regulatory Status

    Pixuvri™: U.S. Regulatory Status FDA appeal: Office New Drugs (OND) provided path for resubmission - 2 Independent Radiographic Panel confirmed 1st panels results - Document Interim analysis was not conducted then PIX301 trial would be considered a positive study EU launch and pacritinib acquisition

  15. Slide 15: A highly differentiated JAK2 inhibitor

    A highly differentiated JAK2 inhibitor

  16. Slide 16: Pacritinib: Inhibits important activating mutations (JAK2 + FLT3)

    Pacritinib: Inhibits 2 important activating mutations (JAK2 + FLT3)

  17. Slide 17: Initial Target Market: MF patients with thrombocytopenia

    Initial Target Market: MF patients with thrombocytopenia (platelets <10 0 x1 0 9 ) Table 2: Maximum Restarting Doses for Jakafi After Safety Interruption* Current Platelet Count Maximum Dose When Restarting Jakafi Treatment * Greater than or equal to 125 X 109/L 20 mg twice daily 100 to less than 12

  18. Slide 18: 27% MF Patients Have Severe Thrombocytopenia

    27% MF Patients Have Severe Thrombocytopenia JAK1/JAK2 inhibitors (ruxolitinib) associated with treatment emergent thrombocytopenia and anemia Pacritinib: selective JAK2 inhibitor lacks myelosupporession; potentially first to market for MF patients with low platelets ( < 100,000/uL ) Source: MPN Res

  19. Slide 19: Pacritinib: Targets patient population unserved by ruxolitinib

    Pacritinib: Targets patient population unserved by ruxolitinib Ruxolitinib approval trials excluded patients <100,00/uL platelets - 93% COMFORT II had normal platelets, median COMFORT I, 244,000/uL - However, MF patients with low platelet counts are higher risk population Ruxolitinib study* (n=41) M

  20. Slide 20: Summary Clinical Trial Results JAK Inhibitors in MF

    Summary Clinical Trial Results JAK Inhibitors in MF Company Drug Stage SX Spleen >50% PE Spleen >35% MRI RBC JAK2 V617F* Platelet cutoff Side Effects Pacritinib Demonstrates a Truly Differentiated Side-Effect Profile Pacritinib JAK2-wt JAK2 V617F FLT-3 Phase 3 (Phase 2 n=65)** >50% 42% 32% NR >30% N

  21. Slide 21: Pacritinib: Phase 2 Studies

    Pacritinib: Phase 2 Studies Source: ASH 2011.

  22. Slide 22: Pacritinib: Phase 2 Studies (combined)

    Pacritinib: Phase 2 Studies (combined) Source: ASH 2011.

  23. Slide 23: Pacritinib: Phase 2 Efficacy (combined)

    Pacritinib: Phase 2 Efficacy (combined) 27 of 65 (42%) patients had response of 50% 14 of 65 (21%) had complete response with resolution of splenomegaly 8 of 26 (32%) treated with SB1518 had 35% reduction by MRI* Source: ASH 2011. *Among patients who had MRI measurements (8 patients did not have bas

  24. Slide 24: Pacritinib: Benefit Independent of Platelet Count

    Pacritinib: Benefit Independent of Platelet Count Assessment Maximum decrease from baseline Patients with baseline platelet counts 150,000 N=36 All Evaluable Patients N=65 PE 50% 14 (39%) 27 (42%) Source: ASH 2011. * Reduction of splenomegaly was observed with similar frequency in patients with norm

  25. Slide 25: Pacritinib: Minimal Effect on Platelet Counts

    Pacritinib: Minimal Effect on Platelet Counts Lack of treatment emergent thrombocytopenia observed in patients with low starting platelet counts Source: Komrokji. R., et al

  26. Slide 26: Pacritinib: Lack of treatment associated anemia

    Pacritinib: Lack of treatment associated anemia Source: Komrokji. R., et al

  27. Slide 27: Pacritinib: Durable Improvement in MF Related Symptoms

    Pacritinib: Durable Improvement in MF Related Symptoms Source: ASH 2011.

  28. Slide 28: Contemplated Phase 3 Trial Designs

    Contemplated Phase 3 Trial Designs Target Indication: • Patients with PMF, PPV-MF, PET-MF with splenomegaly and thrombocytopenia • Two phase 3 trials, each approximately 270 patients - Pacritinib Vs BAT - Pacritinib Vs BAT including patients on low dose ruxolitonib (5,10mg) with treatment emergent t

  29. Slide 29: Pacritinib: Certain Key Deal Terms

    Pacritinib: Certain Key Deal Terms Acquired molecule from S*Bio • S*BIO was established as a joint venture between The Singapore Economic Development Board Investments and Chiron Corporation as Singapore’s first fully- integrated, drug discovery company Upfront payment $30mm • $15 million cash • $15

  30. Slide 30: A new class of cancer targeted agents

    A new class of cancer targeted agents AADR inducers

  31. Slide 31: Tosedostat: Novel Mechanism of Action AADR Inducer

    Tosedostat: Novel Mechanism of Action AADR Inducer Targets members of aminopeptidase family Induces genes characteristic of Amino Acid Deprivation Response (AADR) resulting in cell death AADR changes only seen in transformed (tumor) cells and not normal cells Demonstrated clinical activity across ra

  32. Slide 32: Tosedostat: OPAL Study Results

    Tosedostat: OPAL Study Results Encouraging Phase 2 data - r/r elderly AML (n=73) • Oral once-a-day dosing for 6 months • 16 of 50 (32%) evaluable patients had bone marrow response - 9 (12%) of which were complete bone marrow responses • 9 of 25 (36%) patients who previously failed therapy with HMA h

  33. Slide 33: Tosedostat: Phase 2 Study

    Tosedostat: Phase 3 Study Data support pivotal trial: high risk MDS/secondary AML Phase 3 trial options: • Relapsed/refractory setting combination with LDAC - High risk heterogenous patient population - Several drugs currently targeting this population • st line setting combination with HMA - Substa

  34. Slide 34: Partnership with Chroma Therapeutics

    Partnership with Chroma Therapeutics Exclusive co-development and marketing rights in the Americas • Chroma Therapeutics has ROW rights Cost-sharing • CTI bears 75% of agreed upon direct development expenses • Registration trials aimed at US/EU regulatory approval Initial Payments • $5mm upon execut

  35. Slide 35: Financial Overview

    Financial Overview

  36. Slide 36: Financial Overview Capital Structure and Financial Statistics

    Financial Overview Capital Structure and Financial Statistics Exchanges / Tickers • NASDAQ: CTIC and MTA: CTIC.MI Market Capitalization • ~$125mm Shares Outstanding • ~56.6mm Cash • $24mm (1) Debt • None Projected Cash Burn • ~$4.5mm / month Cash Remaining • January 2013 Estimated Cash Burn (2) • $5

  37. Slide 37: Expected News Flow

    Expected News Flow Upcoming Planned Events • Pixuvri launch in the EU • Pacritinib phase 3 trial initiation in Myelofibrosis • Brostallicin- SABC triple negative breast cancer • OPAXIO interim survival analysis Phase 3 ovarian cancer trial • IQWiG innovation score assignment Upcoming publications •

Cell Therapeutics — Investor Presentation (September 2012) on 6ix